Variants in ATP6V0C are associated with Dravet‐like developmental and epileptic encephalopathy
Authors:
- Marlene RongMRMarlene Rong
- Paula T. MarquesPMPaula T. Marques
- Quratulain Zulfiqar AliQAQuratulain Zulfiqar Ali
- Ricardo MorcosRMRicardo Morcos
- Ilakkiah ChandranICIlakkiah Chandran
- Farah QaiserFQFarah Qaiser
- Rikke S. MøllerRMRikke S. Møller
- Allan BayatABAllan Bayat
- Guido RubboliGRGuido Rubboli
- Elena GardellaEGElena Gardella
- Miriam S. ReuterMRMiriam S. Reuter
- Tristan T. SandsTSTristan T. Sands
Open Access
Abstract
Objective: Dravet syndrome (DS) is a developmental and epileptic encephalopathy. Diagnosis is clinical, but ~90% of patients have pathogenic variants in SCN1A . ATP6V0C has recently been proposed as a novel candidate gene for epilepsy, with or without developmental delay. Here we describe two adult patients with a clinical diagnosis of DS associated with ATP6V0C variants. Methods: Patients with developmental and epileptic encephalopathies were evaluated by physicians who are experts in DS, and their clinical diagnosis was correlated with genetic findings. A subgroup of those patients with DS but without known genetic causes were evaluated through gene panels, whole exome sequencing, and chromosome microarray. Phenotype was determined by pediatric and adult chart reviews, interviews, and physical examinations. Results: Of 753 patients with DS, two unrelated individuals with classic features of DS during childhood and adulthood were identified with heterozygous de novo missense variants in ATP6V0C (c.319G > C, p.(Gly107Arg) and c.284C > T, p.(Ala95Val), respectively). Both variants were absent in normal populations and computational prediction algorithms suggested deleterious effects on protein structure and/or function. No disease‐causing variants in other genes previously associated with DS were found. Significance: Here we describe two adult patients with Dravet‐like syndrome and pathogenic/likely pathogenic variants in ATP6V0C . We propose that abnormal ATP6V0C function can, at the severe end of the clinical spectrum, be associated with Dravet‐like phenotype. This is relevant, as these patients would not qualify for disease‐modifying antisense nucleotide or gene therapies targeting SCN1A .Keywords
This publication has 24 references indexed in Scilit:
- A systematic review of adults with Dravet syndromeSeizure: European Journal of Epilepsy, 2021
- Novel de novo mutation substantiates ATP6V0C as a gene causing epilepsy with intellectual disabilityBrain and Development, 2021
- Haploinsufficiency of ATP6V0C possibly underlies 16p13.3 deletions that cause microcephaly, seizures, and neurodevelopmental disorderAmerican Journal of Medical Genetics Part A, 2020
- A new microdeletion syndrome involving TBC1D24, ATP6V0C, and PDPK1 causes epilepsy, microcephaly, and developmental delayGenetics in Medicine, 2019
- Gene mutational analysis in a cohort of Chinese children with unexplained epilepsy: Identification of a new KCND3 phenotype and novel genes causing Dravet syndromeSeizure: European Journal of Epilepsy, 2019
- Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus PanelPediatric Neurology, 2017
- Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson’s, Alzheimer’s, and psychiatric diseasesThe Journal of Physiological Sciences, 2017
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Progressive Gait Deterioration in Adolescents With Dravet SyndromeArchives of Neurology, 2012
- De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of InfancyThe American Journal of Human Genetics, 2001